SCHEMBL2183200

SCHEMBL2183200

CC(C)(CNC(=O)C(C)(C)C)NC(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.38
DPP4 P27487 1/20 0.35
HDAC6 Q9UBN7 1/20 0.33
PREP P48147 1/20 0.33
FAP Q12884 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA14 Q9ULX7 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
KDM4C Q9H3R0 1/20 0.31
KDM4E B2RXH2 1/20 0.31
TP53 P04637 1/20 0.31
CYP2C19 P33261 2/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25353226 0.83 CYP2D6 (0.39) POLBSMN1; SMN2KDM4CCYP2C19ALDH1A1
SCHEMBL8962237 0.75 POLB (0.38) POLBDPP4HDAC6PREPFAP
SCHEMBL26629354 0.75 PREP (0.40) POLBDPP4HDAC6PREPFAP
SCHEMBL24574899 0.75 SMN1; SMN2 (0.45) POLBDPP4HDAC6PREPFAP
SCHEMBL22991094 0.74 POLB (0.39) POLBDPP4HDAC6PREPFAP
Ammonia Solution, Strong SCHEMBL27973098 0.73 POLB (0.37) POLBDPP4HDAC6PREPFAP
SCHEMBL4478224 0.73 POLB (0.31) POLBKDM4CALDH1A1
SCHEMBL12920690 0.73 CNR2 (0.38) POLBDPP4HDAC6PREPFAP
SCHEMBL12175396 0.72 POLB (0.42) POLBL3MBTL1KDM4CKDM4ECYP2C19
SCHEMBL28001419 0.71 DPP4 (0.32) POLBDPP4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970107-B1 PHOTOSWITCHABLE HDAC INHIBITORS MASSACHUSETTS GEN HOSPITAL (US) 2023-11-15 EP claimed
EP-3538510-B1 PROCESS FOR THE PREPARATION OF MONO-PROTECTED ALPHA,OMEGA-DIAMINO ALKANES BYONDIS BV (NL) 2021-01-06 EP claimed
US-10815194-B2 Process for the preparation of mono-protected α,ω-diamino alkanes BYONDIS B.V. (NL) 2020-10-27 US claimed
EP-3538510-A1 PROCESS FOR THE PREPARATION OF MONO-PROTECTED alpha,omega-DIAMINO ALKANES Synthon Biopharmaceuticals B.V. (NL) 2019-09-18 EP claimed
WO-2018086993-A1 PROCESS FOR THE PREPARATION OF MONO-PROTECTED alpha,omega-DIAMINO ALKANES SYNTHON BIOPHARMACEUTICALS B.V. (NL) 2018-05-17 WO claimed
US-20130304089-A1 PERYLENEQUINONE DERIVATIVES AND USES THEREOF QUEST PHARMATECH INC. (CA) 2013-11-14 US claimed
US-20240125773-A1 COMPOSITIONS AND METHODS FOR PREVENTING NON-SPECIFIC INTERACTIONS BETWEEN POLYMER DYES-ANTIBODY CONJUGATES BECKMAN COULTER, INC. 2024-04-18 US disclosed
EP-4334395-A1 UV-ABSORBING POLYMERS, COMPOSITIONS AND USES THEREOF Beckman Coulter, Inc. (US) 2024-03-13 EP disclosed
US-20240075151-A1 CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS FISH & RICHARDSON PC 2024-03-07 US disclosed
WO-2024044327-A1 DHNT MONOMERS AND POLYMER DYES WITH MODIFIED PHOTOPHYSICAL PROPERTIES BECKMAN COULTER, INC. (US) 2024-02-29 WO disclosed
US-20240052092-A1 PHOTOACTIVE MACROMOLECULES AND USES THEREOF BECKMAN COULTER, INC. 2024-02-15 US disclosed
US-20240011976-A1 ADDITIVES FOR REDUCING NON-SPECIFIC INTERACTIONS BETWEEN FLUORESCENT POLYMER CONJUGATES AND CELLS IN A BIOLOGICAL SAMPLE BECKMAN COULTER, INC. 2024-01-11 US disclosed
WO-2024007016-A2 NOVEL FLUORESCENT DYES AND POLYMERS FROM DIHYDROPHENANTHRENE DERIVATIVES BECKMAN COULTER, INC. (US) 2024-01-04 WO disclosed
EP-2638009-A2 FLUORINATED HDAC INHIBITORS AND USES THEREOF President and Fellows of Harvard College (US) 2013-09-18 EP disclosed
WO-2013070943-A2 SMALL MOLECULE SCREEN FOR INHIBITORS OF NFAT:AP-1:DNA INTERACTIONS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2013-05-16 WO disclosed
US-20130040998-A1 FLUORINATED HDAC INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-02-14 US disclosed
WO-2012112922-A1 METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES ALEXION PHARMACEUTICALS, INC. (US) 2012-08-23 WO disclosed
US-20120208889-A1 CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUE, INC. (US) 2012-08-16 US disclosed
US-20120178940-A1 Functionalized Polymers QUIAPEG AB (SE) 2012-07-12 US disclosed
WO-2011084991-A2 FLUORINATED HDAC INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130304089-A1 PERYLENEQUINONE DERIVATIVES AND USES THEREOF CYP27B1, CYP27A1, PCNA POLB 591/4885DPP4 4078/4885HDAC6 4066/4885
US-20120178940-A1 Functionalized Polymers PARG, PUF60, PCBP1 POLB 669/4885DPP4 4592/4885HDAC6 636/4885
US-10815194-B2 Process for the preparation of mono-protected α,ω-diamino alkanes FCGRT, CD22, DEGS1 POLB 347/4885DPP4 850/4885HDAC6 2417/4885
US-20240075151-A1 CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS TNF, TNFRSF1A, TNFSF11 POLB 2216/4885DPP4 4064/4885HDAC6 624/4885
US-20130040998-A1 FLUORINATED HDAC INHIBITORS AND USES THEREOF HDAC1, HDAC5, HDAC6 POLB 1226/4885DPP4 2274/4885HDAC6 3/4885
US-20120208889-A1 CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF HDAC1, HDAC5, HDAC6 POLB 3822/4885DPP4 2528/4885HDAC6 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.